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Poxvirus infections continue to threaten human health despite the eradication of 
smallpox, which was one of the most lethal infectious diseases in human history. Our objectives 
were to identify the host cell components/functions that are important for poxvirus infection and 
to gain insights into the molecular mechanism of poxvirus replication, ultimately guiding novel 
anti-viral development. Using vaccinia virus, the prototype poxvirus, we screened inhibitors of 
viral replication from over 3,000 chemical compounds, most of which have known cellular 
targets. This screening revealed numerous JAK/STAT3 inhibitors that could inhibit the 
replication of vaccinia virus. We further used multiple inhibitors of the JAK/STAT3 pathway 
and tested their effects on the replication of vaccinia virus in multiple primary and transformed 
cells through reporter assay and viral infectious particles measurement. The JAK/STAT3 
inhibitors being tested were: SC144, an inhibitor of the interleukin 6(IL-6), receptor of the 
JAK/STAT3 signaling pathway, AZ960 (a JAK2 inhibitor), Stattic and niclosamide (inhibitors of 
STAT3). Overall, our data indicate the JAK/STAT3 inhibitors could repressed vaccinia virus 
replication in multiple cell types, suggesting that the JAK/STAT3 signaling pathway is required 
for the efficient replication of vaccinia virus. Moreover, we observed that STAT3 was enriched 
in the cell nucleus, although the phosphorylation level of STAT3 was downregulated in vaccinia 
virus-infected cells during the early stages of infection. This study demonstrates an important 
role of the JAK/STAT3 signaling pathway in the replication of vaccinia virus, providing a 
possible novel direction by which to intervene in poxvirus infection and related diseases. 
 iv 
Table of Contents 
List of Figures ................................................................................................................................ vi 
Chapter 1 - Literature review .......................................................................................................... 1 
Poxvirus .................................................................................................................................. 1 
Vaccinia virus ......................................................................................................................... 3 
Vaccinia virus–host cell interactions ...................................................................................... 5 
JAK/STAT3 signaling............................................................................................................. 7 
JAK/STAT3 inhibitors ............................................................................................................ 9 
JAK/STAT3 signaling in viral infections ............................................................................. 10 
References ................................................................................................................................. 12 
Figures ...................................................................................................................................... 23 
Chapter 2 - JAK/STAT3 inhibitors repress vaccinia virus infection ............................................ 25 
Abstract ..................................................................................................................................... 25 
Introduction ............................................................................................................................... 26 
Materials and methods .............................................................................................................. 28 
Cell cultures .......................................................................................................................... 28 
Chemical inhibitors ............................................................................................................... 28 
MTT assay............................................................................................................................. 28 
Viruses, viral infection, and plaque assays ........................................................................... 29 
Gaussia luciferase assay ........................................................................................................ 30 
Plaque assay .......................................................................................................................... 30 
Statistical analysis ................................................................................................................. 30 
Results ....................................................................................................................................... 31 
Identification of JAK/STAT3 inhibitors that suppress replication of vaccinia virus ........... 31 
Chemical inhibitors of the JAK/STAT3 pathway repress gene expression in vaccinia virus
 ............................................................................................................................................... 31 
JAK/STAT3 inhibitors repress gene expression of vaccinia virus in keratinocytes ............. 33 
The cytotoxicity of niclosamide on NHDFs and the inhibitory effects of niclosamide on 
replication of vaccinia virus .................................................................................................. 34 
 v 
The cytotoxicity of SC144 on NHDFs and the inhibitory effects of SC144 on replication of 
vaccinia virus in NHDFs ....................................................................................................... 34 
The cytotoxicity of SC144 on HeLa cells and the inhibitory effects of SC144 on vaccinia 
virus in HeLa cells ................................................................................................................ 35 
Discussion ................................................................................................................................. 35 
References ................................................................................................................................. 38 
Figures ...................................................................................................................................... 42 
Chapter 3 - Construction of recombinant vaccinia virus with an IPTG-inducible phosphatase, H1
 ............................................................................................................................................... 49 
Abstract ..................................................................................................................................... 49 
Introduction ............................................................................................................................... 50 
Materials and methods .............................................................................................................. 51 
Cell cultures .......................................................................................................................... 51 
Viral infection and titration ................................................................................................... 52 
Construction of an isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible recombinant 
vaccinia virus, viH1L ............................................................................................................ 52 
Preparation and isolation of the recombinant viH1L vaccinia virus ..................................... 52 
Immunoblotting analysis ....................................................................................................... 53 
Results and discussion .............................................................................................................. 53 
Phosphorylation of STAT3 decreases in vaccinia virus-infected cells, whereas total STAT3 
is enriched in the cell nucleus ............................................................................................... 53 
Construction of the IPTG-inducible recombinant viH1L vaccinia virus expressing green 
fluorescent protein (GFP) reporter gene ............................................................................... 54 
Repression of H1 phosphatase in vaccinia virus decreases the production of infectious 
particles ................................................................................................................................. 55 
Future perspectives ................................................................................................................... 56 
References ................................................................................................................................. 56 
Figures ...................................................................................................................................... 58 
Chapter 4 - Summary and future perspectives .............................................................................. 65 
References ................................................................................................................................. 67 
  
 vi 
List of Figures 
Figure 1-1 The lifecycle of the vaccinia virus .............................................................................. 23 
Figure 1-2 The JAK/STAT pathway............................................................................................. 24 
Figure 2-1 Schematic of chemical screen for inhibitors of vaccinia virus ................................... 42 
Figure 2-2 Small chemical inhibitors target the JAK/STAT3 pathway ........................................ 43 
Figure 2-3 Effects of inhibitors of the JAK/STAT3 pathway on gene expression in vaccinia virus
 ............................................................................................................................................... 44 
Figure 2-4 Effects of STAT3 inhibitors on late gene expression of vaccinia virus in primary 
human keratinocytes (HFKs) ................................................................................................ 45 
Figure 2-5 The cytotoxicity and the inhibitory effects of niclosamide on normal human dermal 
fibroblasts (NHDFs) and replication of vaccinia virus ......................................................... 46 
Figure 2-6 The cytotoxicity and the inhibitory effects of SC144 on NHDFs and replication of 
vaccinia virus ........................................................................................................................ 47 
Figure 2-7 The cytotoxicity and the inhibitory effects of SC144 on HeLa cells and replication of 
vaccinia virus in HeLa cells .................................................................................................. 48 
Figure 3-1 Phosphorylation of STAT3 in vaccinia virus-infected cells and total STAT3 in the cell 
nucleus .................................................................................................................................. 58 
Figure 3-2 IPTG-inducible Vac/T7 recombinant vaccinia virus system ...................................... 59 
Figure 3-3 Generation of the recombinant vaccinia virus viH1L ................................................. 60 
Figure 3-4 Generation of the recombinant vaccinia virus viH1L through PCR and recombinant 
technology ............................................................................................................................. 61 
Figure 3-5 Confirmation of successful generation of the three fragments of recombinant vaccinia 
virus viH1L by PCR .............................................................................................................. 62 
Figure 3-6 Confirmation of successful generation of the recombinant vaccinia virus viH1L by 
Sanger sequencing................................................................................................................. 63 
Figure 3-7 Effects of the presence of IPTG on the production of infectious particles by the 
recombinant vaccinia virus viH1L and the Western Reserve (WR) strain of vaccinia virus 64 
 
1 
Chapter 1 - Literature review 
Poxvirus 
Poxviruses are large, enveloped, double-stranded DNA viruses that infect insects 
(Entomopoxvirinae) and chordates (Chordopoxvirinae). Within the Chordopoxvirinae subfamily, 
species that can infect humans are found in four genera: Molluscipoxvirus, Orthopoxvirus, 
Parapoxvirus, and Yatapoxvirus (Marennikova & Moyer, 2005). Several species from the 
Orthopoxvirus genus are well-known poxviruses that cause outbreaks among humans and other 
animals. The most notorious disease associated with poxviruses is smallpox, caused by the 
variola virus (Orthopoxvirus genus). Smallpox was the deadliest disease in human history 
(Marennikova & Shchelkunov, 2005), and the annihilation of smallpox through global 
vaccination is one of the greatest triumphs of modern medicine (Smith & McFadden, 2002). 
Nevertheless, poxviruses continue to pose threats to human health long after the World Health 
Organization certified the world free of smallpox in 1980. 
Monkeypox (Orthopoxvirus genus) is one fatal poxvirus that also infects humans. Human 
monkeypox has been endemic to central and west African countries ever since it was recognized 
as a human disease in 1970 (Durski et al., 2018). The spread and mortality rate of monkeypox is 
increasing. Many countries that had not reported a single case in several decades have started to 
experience large-scale monkeypox outbreaks. Recently, there were 172 suspected and 61 
confirmed cases of monkeypox infection reported in Nigeria in 2017 (“WHO | Monkeypox – 
Nigeria,” n.d.). Currently, the fatality rate of monkeypox in persons without vaccination is 11% 
(Durski et al., 2018). Vaccination against smallpox can provide cross-protection against 
monkeypox (“Monkeypox | Poxvirus | CDC,” n.d.); however, the majority of young adults are 
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susceptible to monkeypox infection due to the cessation of the smallpox vaccination program in 
1980 (Smith & McFadden, 2002). 
Poxviruses can also infect domestic animals and cause economic loss in many countries. 
For instance, goatpox and sheeppox cause skin lesions in infected animals, resulting in weight 
loss, reduction of milk, and loss of wool (Yune & Abdela, 2017). Moreover, poxvirus infection 
in domestic animals weakens the immune system, which directly or indirectly leads to the death 
of livestock (Babiuk, Bowden, Boyle, Wallace, & Kitching, n.d.). In addition to economic 
impact, poxvirus infections in animals often lead to human zoonotic poxvirus outbreaks that are 
potential threats to human society. 
Zoonotic poxvirus outbreaks alarm the possible returning of smallpox or even more lethal 
poxvirus plagues. Furthermore, there have also been fears of terrorists using variola virus as a 
bioterrorism weapon since the eradication of smallpox (Sharma, 2002). In 2017, a team from 
Canada successfully generated a horsepox virus, another poxvirus currently extinct in nature, 
through biosynthesis and recombination (Noyce, Lederman, & Evans, 2018). Their publication 
suggested that it is possible to generate the variola virus or an even more deadly virus through 
biosynthesis and recombination technology. 
Currently, there is no specific treatment for poxvirus infection, although vaccination can 
offer cross-protection against poxvirus infection (“Monkeypox | Poxvirus | CDC,” n.d.). Several 
antiviral drugs have shown effective inhibition towards poxvirus infection in a laboratory setting. 
Tecovirimat (Berhanu et al., 2015), Cidofovir (De Clercq, 2002), and Brincidofovir (Foster, 
Parker, & Lanier, 2017) are recommended treatments against poxvirus infection, despite the fact 
that they have not yet been tested on patients (“Prevention and Treatment | Smallpox | CDC,” 
2017). Promising as it appears, poxvirus antiviral therapy is challenged by drug resistance. 
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Tecovirimat (also called ST-246), the antiviral medicine being stockpiled at the Center for 
Disease Control to combat potential poxvirus attacks, has been reported to interact with virion 
membrane protein F13L (Yang et al., 2005). Mutation within the F13L gene results in poxviruses 
that are resistant to ST-246 treatment (Duraffour et al., 2015). Due to the scarcity of antiviral 
medicines against poxvirus infection, it is necessary and essential to study the biology of 
poxviruses in order to assist in the discovery of antiviral drugs against current and potential 
poxvirus outbreaks. 
Vaccinia virus 
Vaccinia virus (Orthopoxvirus genus), an archetypal member of the poxvirus family, was 
used as a vaccine in the global eradication program against smallpox (Smith & McFadden, 
2002). The global smallpox eradication program eliminated naturally-occurring smallpox; 
however, it also helped spread the vaccinia virus all over the world. Several sub-lineage strains 
of vaccinia virus have caused outbreaks among domestic animals and humans in various 
locations worldwide (Singh, Balamurugan, Bhanuprakash, Venkatesan, & Hosamani, 2012). 
Most recently, vaccinia virus has caused bovine vaccinia outbreaks in Brazil (Miranda et al., 
2017). The cessation of the smallpox vaccine campaign has put human society in a dangerous 
position because the vaccinia virus has been spread all over the world. Despite vaccinia virus 
being one of the most well-studied viruses, the origin and natural reservoir of vaccinia virus 
remains a mystery (McFadden, 2005). Vaccinia virus has a large host range, infecting both wild 
and domestic animals, as well as humans. It is possible that more dangerous strains of vaccinia 
virus are being generated through evolution in nature. 
Despite being a causative agent for several outbreaks worldwide, vaccinia virus is 
frequently used as a research tool in the study of poxviruses. Vaccinia virus, which replicates 
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entirely in the cytoplasm of the host cell (Moss, 2013b), possesses a transcriptional system. The 
vaccinia virus possesses a transgene upload capability of approximately 25 kb (Smith & Moss, 
1983) that makes it a perfect vector for the expression of foreign proteins in mammalian cells 
(Chakrabarti, Sisler, & Moss, 1997). Recombinant vaccinia virus-based vector systems have 
been used to engineer vaccines to combat various infectious diseases. The vaccinia–rabies 
recombinant oral vaccine (Pastoret & Brochier, 1996), which has been applied to control wildlife 
rabies among foxes in several European countries and the United States, uses recombinant 
vaccinia virus as a vector. A system called “Sementis Copenhagen Vector” that is a vaccinia-
based vaccine vector, allows multiple antigens to be expressed in a single vector (Prow et al., 
2018). Moreover, the fact that vaccinia virus can rapidly replicate, spread to tumor tissue, and 
perform active lytic activity makes it a great candidate as an oncolytic agent (Mansfield et al., 
2016). 
The lifecycle of vaccinia virus (Figure 1-1) consists of several steps: cell entry, gene 
expression, DNA replication, virion assembly, and exit (Moss, 2013a). Vaccinia virus infectious 
particles enter the cell through direct fusion with the host cell membrane or endocytosis. Early 
gene expression then starts directly after the virus core enters the host cell cytoplasm (Gershon & 
Moss, 1990). Vaccinia virus encodes factors and enzymes for early gene expression, which are 
packaged in the core of infectious particles at the late stage of infection. Early genes encode 
factors that transactivate intermediate gene expression and DNA replication. Newly synthesized 
viral DNA then functions as a template for intermediate and late gene expression. The three 
stages of gene expression are regulated in a progressive manner (Yang, Martens, Bruno, 
Porcella, & Moss, 2012). Following late gene expression, viral proteins and genomes are 
assembled into virions in viral factories, which are granular, restricted areas in an infected cell’s 
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cytoplasm. Viral factories are also responsible for the maturity of virions, including packaging 
genome and core proteins into immature virions, assembling crescent membranes with immature 
virions, and producing infectious particle mature virions (Condit, Moussatche, & Traktman, 
2006). Mature virions can be released either by cell lysis or by transferring through the host cell 
endoplasmic reticulum to gain host cell plasma membranes and then exiting the cell through 
exocytosis. Host–viral interaction occurs throughout the lifecycle of vaccinia virus. Viral factors 
are released during viral entry and interact with host proteins to promote survival of the virus. A 
clear picture of the infection cycle of vaccinia virus in host cells provides insights for antiviral 
developments. 
Vaccinia virus–host cell interactions 
As with all other viruses, the vaccinia virus has developed numerous strategies for 
surviving in hosts over years of evolution. Host antiviral immune response is a critical barrier for 
pathogen invasion. Vaccinia virus deploys factors that directly bind to and neutralize cytokines 
and chemokines, or indirectly inhibit apoptosis and signaling pathways, reducing the production 
of factors that contribute to immune response (Smith et al., 2013). 
Regarding immune evasion, vaccinia virus has been reported to interfere with the host 
NF-B pathway, which is a critical signaling pathway that regulates inflammatory and immune 
response (Gómez et al., 2012). Multiple factors targeting different sites of the NF-B pathway 
can be used to achieve total suppression. These factors include the viral factors, M2L (Gedey, 
Jin, Hinthong, & Shisler, 2006) that represses ERK2 phosphorylation; K1L (Shisler & Jin, 2004) 
that reduces IB degradation; and B14 (Benfield et al., 2011) that binds to IKK, further 
inhibiting NF-B activation. 
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Interferon response is pivotal in innate immune response that makes it a primary target 
for pathogen during their invasion (Samuel, 2001). The induction of a series of effectors, named 
interferon-stimulated genes (ISGs), is the primary effects of interferon activation (Schoggins et 
al., 2011). Interferon response encompasses interferon production and interferon signaling, 
which further activates the Janus kinase (JAK)/signal transducer and activator of transcription 1 
(STAT1) pathway, resulting in the production of ISGs (Ivashkiv & Donlin, 2014). Vaccinia virus 
encodes several factors that specifically interfere with interferon production and signaling 
pathways (Smith, Talbot-Cooper, & Lu, 2018). Vaccinia virus secretes soluble / interferon 
receptors that bind to the host membrane to prevent interferon response (Alcamı,́ Symons, & 
Smith, 2000). A dual-specificity phosphatase (H1) encoded by vaccinia virus is responsible for 
repressing the type I interferon response by dephosphorylating activated STAT1 during infection 
(Najarro, Traktman, & Lewis, 2001). Additionally, the vaccinia virus’s E3 protein binds to 
ISG15, a ubiquitin-like modifier, to prevent its antiviral functions (Guerra, Cáceres, Knobeloch, 
Horak, & Esteban, 2008). 
In addition to immune evasion, vaccinia virus also manipulates host machinery to benefit 
its replication. For example, it hijacks host translational machinery for viral protein synthesis 
(Moss & Salzman, 1968). Inhibition of the apoptosis pathway is another common strategy 
through which viruses prolong their replication within infected host cells. Vaccinia viral anti-
apoptosis protein F1L, a B-cell CLL/lymphoma 2(Bcl-2) homolog, inhibits host apoptosis by 
blocking the release of cytochrome c (Wasilenko, Banadyga, Bond, & Barry, 2005). 
The interactions among vaccinia viruses and host cells are complicated, and many 
unknown interplays await exploration. Understanding more about the biology of vaccinia virus 
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infection benefits the human species as a whole, allowing us to survive potential poxvirus 
outbreaks. 
JAK/STAT3 signaling 
Janus kinases (JAKs) are a family of non-receptor cytoplasmic tyrosine kinases that are 
constitutively associated with cytokine and chemokine receptors (Yu, Pardoll, & Jove, 2009). In 
mammals, the JAK family consists of four members: JAK1, JAK2, JAK3, and tyrosine kinase 
(TYK2). JAKs can phosphorylate downstream factors in the cytoplasm upon activation 
(Yamaoka et al., 2004). The STAT family comprises transcription factors that can be activated 
by JAKs and transduce signals from the cytoplasm to the nucleus (Yu, Lee, Herrmann, Buettner, 
& Jove, 2014). The STAT family shares several highly conserved domains (Figure 1-2), 
including the amino-terminal domain (N), the coil-coil domain (CC), the DNA-binding domain 
(DBD), the linker domain (LK), the Scr homolog domain (SH2), the tyrosine phosphorylation 
site (Y), and the transactivation domain (TAD). Upon ligand binding, receptors located on the 
cell membrane go through conformational changes and activate a pair of JAKs that are 
constitutively associated with their intracellular domain. Active JAKs then phosphorylate the 
intercellular domain of receptors and themselves to provide docking sites, and further 
phosphorylate specific tyrosine residues within the TAD domain of downstream STATs. 
Phosphorylated monomer STATs can form dimers (homo- or hetero-) through reciprocal 
interactions among their SH2 domain phosphorylated tyrosine residues, which are then released 
from receptors and translocate to the nucleus (Yu et al., 2009). After nucleus translocation, 
STAT dimers function as transcription factors and regulate expression of specific genes 
(Peng Lim & Cao, 2006). Even though members of the STAT family share similar structures and 
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activation pathways, specific extracellular signals preferentially stimulate certain types of STATs 
and exert different functions (O’Shea et al., 2015). 
STAT3, a member of the STAT family, plays a central role in many physiological and 
pathological pathways. It interacts with various factors and has different functions based on 
cellular context. STAT3 regulates a broad range of physiological functions, such as 
development, differentiation, immunity, and metabolism, as well as exhibiting pathological over-
expression in many cancer tissues (Siveen et al., 2014). STAT3 was initially described as a 
DNA-binding factor that can transduce signals from interferons and interleukin 6 (IL-6; Darnell, 
Kerr, & Stark, 1994). Many extracellular stimuli can activate STAT3, such as growth factors, 
cytokines, stress, and infection (Hu et al., 2018). In addition to its involvement in the classic 
JAK/STAT3 signaling pathway, unphosphorylated STAT3 can form dimers and regulate gene 
expression in the nucleus (Nkansah et al., n.d.). 
STAT3 is essential for many aspects of development, especially immune development 
(Takeda et al., 1998). Mice with knockdown of STAT3 are more susceptible to infection due to 
the critical role STAT3 plays in the development of the innate and adaptive immune systems 
(Akira, n.d.). STAT3 is also involved in inflammation in tissues with chronic infection (Welte et 
al., 2003). Many cancer patients have histories of chronic viral infection and, correspondingly, 
highly elevated STAT3 levels. The fact the STAT3 is involved in immune response and anti-
apoptosis makes this pathway both beneficial and harmful for viral infection. Vaccinia virus 
deploys factors to encourage anti-apoptosis in order to prolong its infection. Meanwhile, 
inhibitory effects on host immune response are also essential for the virus’s survival in the host. 
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JAK/STAT3 inhibitors 
The IL-6/JAK/STAT3 axis is hyperactive in many types of cancer, and inhibitors 
targeting this pathway have been under development for decades. Currently, there two common 
strategies to repress the IL-6/JAK/STAT3 pathway: blocking the phosphorylation of STAT3 by 
inhibiting the upstream activation pathway, or directly inhibiting the STAT3 protein by binding 
to its SH2 domain (Johnson, O’Keefe, & Grandis, 2018). 
Several interference approaches, such as antisense oligonucleotides, small interfering 
RNA, peptide-based inhibitors, and small molecule inhibitors, have shown effective blocking of 
STAT3 activation (Furtek, Backos, Matheson, & Reigan, 2016). Among the currently available 
approaches, small molecule inhibitors are gaining more attention due to several features, 
including simple structure, permeability to the cell membrane, and stability. Below are several 
examples of IL-6/JAK/STAT3 small molecule inhibitors. 
One small molecule, 2-(7-Fluoropyrrolo[1,2-a]quinoxalin-4-yl) 2-pyrazinecarboxylic 
acid hydrazide hydrochloride (SC144), binds to the IL-6 receptor GP130 and induces its 
phosphorylation and deglycosylation to repress IL-6/JAK/STAT3 signaling (Xu, Grande, 
Garofalo, & Neamati, 2013). SC144 is the first oral bioactive drug available that targets GP130, 
which shows selective inhibition of STAT3 activation over other STAT proteins. 
Many JAK inhibitors are currently available as FDA-approved drugs to treat autoimmune 
diseases. Since the publication of the kinase and pseudokinase domain structures of JAK1, 
JAK2, and TYK2, many inhibitors have been identified that target ATP-binding sites of JAK 
kinase and pseudokinase domains. These include pan-JAK inhibitors (e.g., gandotinib) that non-
differentially repress all JAKs, and inhibitors that selectively inhibit one type of JAK (e.g., 
AZ960, which selectively suppresses JAK2; Vainchenker et al., 2018). Due to the structural 
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similarity of STATs, activated JAKs are shared among several STATs. Inhibition of upstream 
JAKs has shown promising results in repressing STAT3; however, the effects are not specific. In 
contrast, small molecule inhibitors that directly interfere with the STAT3 protein exhibit fewer 
off-target effects. 
Many functional domains within the STAT3 protein can be target sites for the 
development of inhibitors; however, currently, only inhibitors that interact with the SH2 domain 
of the STAT3 protein are primarily explored. Scientists have tried several strategies to drug the 
SH2 domain of STAT3. Some small molecules have shown efficacy with reducing STAT3 
phosphorylation, dimerization, nucleus translocation, and gene expression in vivo and in vitro 
(Kolosenko et al., 2017). Stattic is one of the first few small molecules to directly target STAT3 
and repress its activation (Schust, Sperl, Hollis, Mayer, & Berg, 2006). Stattic was thought to 
suppress STAT3 by interfering with the SH2 domain specifically; however, later on, it was found 
to alkylate the cysteine residues of many molecules in the cytoplasm (Heidelberger et al., 2013). 
Since the identification of Stattic, researchers have been trying to identify other small molecules 
that repress STAT3 through interference with the STAT3 SH2 domain with higher specificity 
(Yue & Turkson, 2009). With better understanding, there are currently many STAT3 inhibitors 
with good specificity and fewer known off-target effects (Furtek et al., 2016). For instance, 
niclosamide is an FDA-approved anthelmintic medicine and has shown efficient and selective 
inhibition effects on the STAT3 activation (Ren et al., 2010). 
JAK/STAT3 signaling in viral infections 
Interferons and cytokines regulate a series of physiological functions through the 
JAK/STAT pathway. STAT1 and STAT2 are the most well-characterized STATs that are 
involved in interferon response, whereas the role of STAT3 in viral infections is more 
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complicated (Kuchipudi, 2015). Regarding its role in immune response, STAT3 is reported to 
negatively regulate STAT1-mediated type I interferon response (Wang, Levy, & Lee, 2011), 
while also acts as a critical factor in the adaptive immune response (Takeda et al., 1998). The 
involvement of STAT3 in many signaling pathways, as well as its role as a central factor that 
regulates a broad range of physiological activities, demonstrates how complicated its role in viral 
infections is. Indeed, many viruses infection repressed the function of STAT3 while many other 
viruses infection activated it (Kuchipudi, 2015). 
After the viral invasion, various factors, which are products of the host’s acute phase 
response, can stimulate STAT3 activation. Because STAT3 signaling is related to inflammatory 
response and anti-apoptosis pathways, many viruses have evolved to employ STAT3 signaling to 
prolong their infection (Suarez, Van Renne, Baumert, & Lupberger, 2018). Human hepatitis B 
virus, an onco-virus, up-regulates STAT3 activation dependent and independent of the IL-
6/JAK/STAT3 signaling pathway (Hösel et al., 2017). Zika virus also activates IL-6/JAK/STAT3 
signaling (Zhu et al., 2017), which assists its persistence in the central nervous system and lymph 
nodes of monkeys (Aid et al., 2017). 
Virus-mediated suppression of STAT3 is observed in many types of viral infections, most 
likely because STAT3 activation can upregulate expression of genes that are responsible for 
immune response. The mumps virus deploys a viral protein, called V, to eliminate STAT1 and 
STAT3 through ubiquitylation and degradation (Ulane, Rodriguez, Parisien, & Horvath, 2003). 
Similarly, the rabies virus antagonizes STAT3 with a viral protein, called P protein, which 
inhibits STAT3 nuclear translocation and GP130-dependent signaling (Lieu et al., 2013). 
A couple of papers have suggested that the JAK/STAT3 pathway plays a role in antiviral 
defense during vaccinia virus infection. Two previously published papers have demonstrated that 
12 
repressing the JAK/STAT3 pathway, both in human keratinocytes and in a murine model, 
impairs host cell interferon response during vaccinia virus infection (He et al., 2014; Mahony et 
al., 2017). These reports are contradictory to our unbiased screening assay, which showed that 
many JAK/STAT3 inhibitors suppress vaccinia virus replication, as is demonstrated in the next 
chapter. These discrepancies will be discussed in detail, as well. 
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Figure 1-1 The lifecycle of the vaccinia virus 
The lifecycle of the vaccinia virus includes virus entry, early gene expression, DNA replication, 
intermediate gene expression, late gene expression, virus assembly, and virus exit. Vaccinia virus 
infectious particles enter cells through membrane fusion and endocytosis. Early gene expression 
is initiated directly after virus entry, with the assistance of enzymes and factors packaged in the 
virus core. Early genes then encode factors and enzymes for DNA replication and intermediate 
gene expression. Newly synthesized viral DNA functions as a template for intermediate and late 
gene expression. Intermediate genes produce factors to regulate late gene expression. Late genes 
then express enzymes and factors that are required for early gene expression, and the products of 
late gene expression are packaged into the viral core. Vaccinia virus viral assembly takes place in 
a restricted area within the host cell cytoplasm, called the viral factory. In the viral factory, viral 

















Figure 1-2 The JAK/STAT pathway 
A: STAT family members share several highly conserved structures: the amino-terminal domain 
(N), the coil-coil domain (CC), the DNA-binding domain (DBD), the linker domain (LK), the 
Scr homolog domain (SH2), the tyrosine phosphorylation site (Y), and the transactivation 
domain (TAD). 
B: Extracellular stimuli can activate receptors on the cell membrane, resulting in the receptors 
undergoing conformational change. This conformational change brings JAKs together and 
allows self-phosphorylation. Phospho-JAKs recruit and phosphorylate downstream STATs by 
interacting with the SH2 domain. Phosphorylated STATs dimerize and translocate to the cell 
nucleus. Nuclear STAT dimers bind to DNA regulatory elements and function as transcriptional 
factors, modulating gene expression. 
  












Chapter 2 - JAK/STAT3 inhibitors repress vaccinia virus infection 
Abstract 
Poxviruses continue to threaten human health even after the eradication of the historical 
smallpox plague through a global vaccination program. There is no specific treatment for 
poxvirus infection. A better understanding of critical host cell functions in poxvirus replication is 
vital for drug development against poxvirus infection. Our goal is to identify host 
functions/factors that are essential for vaccinia virus infection. To achieve this objective, we 
developed an assay suitable for high throughput screening of chemical inhibitors based on the 
vLGluc recombinant vaccinia virus expressing the secreted gaussia luciferase gene. We screened 
vaccinia virus inhibitors from two libraries, bioactive compounds (Selleck Chemicals) and FDA-
approved drugs, totaling over 3000 chemical compounds, most of which have known cellular 
targets. The screening identified and confirmed numerous inhibitors of vaccinia virus, many of 
which target the JAK/STAT3 signaling pathway. We further investigated the effects of multiple 
JAK/STAT3 inhibitors on vaccinia virus infection. Our results demonstrated that these 
JAK/STAT3 inhibitors significantly inhibited vaccinia virus replication, suggesting that the 




Poxviruses continue to pose threats to human health after the eradication of smallpox, one 
of the most lethal infectious diseases in human history (Smith & McFadden, 2002). There are 
concerns about using variola virus, a causative agent of smallpox, as it could be transformed into 
a bioterrorism weapon. Indeed, the successful laboratory synthesis of a horsepox virus indicates 
the possibility of biosynthesizing smallpox (Noyce et al., 2018). In addition, zoonotic poxviruses 
undermine the safety of human society, such as the monkeypox virus (Durski et al., 2018), which 
causes infection in both humans and domestic animals. Currently, there is no specific treatment 
for poxvirus infection. Understanding more about the interaction between host cells and 
poxviruses is vital for antiviral therapy development against potential poxvirus attacks. 
Vaccinia virus, the archetypal member of the poxvirus family, is an enveloped, double-
stranded DNA virus that contains an approximately 200-kb genome (Moss, 2013b). It replicates 
entirely in the host cell cytoplasm and has its own transcriptional system (Smith et al., 2013). 
Vaccinia virus was used as a vaccine to eradicate smallpox; now, it is used as a vector in vaccine 
development for other infectious diseases and as a research tool in biological studies 
investigating the features of poxviruses (Moss, 2013a). 
Over thousands of years of evolution, viruses have evolved numerous tactics for 
manipulating host cell machinery to support viral replication. Our objective was to identify host 
cellular components that are essential for poxvirus infection and replication. The Yang 
laboratory established an assay suitable for high-throughput screening based on a reporter 
recombinant vaccinia virus expressing the secreted gaussia luciferase reporter gene. After 
screening over 3000 bioactive compounds and FDA-approved drugs with known cellular targets, 
numerous inhibitors of vaccinia virus replication were identified, including chemicals that target 
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cellular functions known to be essential for vaccinia virus replication (Dr. Peng Chen, personal 
communication; Figure 2-1). Many of these inhibitors target the Janus kinase (JAK)/signal 
transducer and activator of transcription 3 (STAT3) pathway, suggesting a supporting role of this 
cell signaling pathway in the replication of vaccinia virus. 
STAT3 is a crucial regulator of many physiological processes, including development, 
differentiation, immunity, and metabolism, as well as being over-expressed in many types of 
cancer tissues (Siveen et al., 2014). STAT3 can be activated through the JAK/STAT3 pathway to 
enact different cellular functions, such as anti-apoptosis, anti-inflammation, proliferation, and 
immune response, based on cell type and extracellular signals (Darnell et al., 1994). The 
JAK/STAT3 pathway is known to be activated during pathogen invasion as a part of the acute 
phase response (Cray, Zaias, & Altman, 2009). Because the JAK/STAT3 pathway plays a pivotal 
role in innate and adaptive immune response, many types of viruses are known to antagonize it 
during infection through various methods; however, this pathway is also reported to be 
hyperactive during various kinds of viral infection due to its effect on cell proliferation and anti-
apoptosis (Gong, Waris, Tanveer, & Siddiqui, 2001; Hösel et al., 2017). 
Our screening results suggest that JAK/STAT3 is required for vaccinia virus replication. 
Here, we employed multiple inhibitors that target different sites of the pathway and tested their 
effects on viral replication using normal human dermal fibroblasts (NHDFs), HeLa cells, and 
keratinocytes. Our results indicate that inhibitors that target multiple components of the 
JAK/STAT3 pathway indeed repress the replication of vaccinia virus. 
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Materials and methods 
Cell cultures 
All cells were cultured in a 37°C incubator with a supplement of 5% CO2. HeLa cells 
(ATCC CCL-2) and normal human dermal fibroblasts (NHDFs; ATCC PCS 201-010) were both 
cultivated in Dulbecco’s Modified Eagle Medium (DMEM) with the addition of 10% fetal 
bovine serum (FBS), 2 mM glutamine, and 1% penicillin-streptomycin. BS-C-1 cells were 
cultured in Eagle’s Minimum Essential Medium (EMEM) with the addition of 10% FBS, 2mM 
glutamine, and 1% penicillin-streptomycin. Primary human keratinocytes (HFKs; kindly 
provided by Dr. Nicholas Wallace) were cultured in defined Keratinocyte-SFM medium. 
Chemical inhibitors 
The chemical inhibitors Stattic, AZ960, and SC144 were purchased from Selleck 
Chemicals. Niclosamide was purchased from Sigma. 
MTT assay 
A 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay was 
performed to measure the cytotoxicity of chemical inhibitors on cells. NHDFs, HFKs, or HeLa 
cells were placed in a 96-well plate at a density of 3.2 x 104 per well. NHDFs and HeLa cells 
were refreshed with pre-warmed DMEM medium with supplement of 2.5% FBS, 2 mM 
glutamine, and 1% penicillin-streptomycin in the presence of dimethyl sulfoxide (DMSO) or the 
desired concentration of chemical inhibitors, and then incubated for 8 or 24 hours. HFKs were 
refreshed with pre-warmed Gibco medium in the presence of DMSO or chemical inhibitors, and 
then incubated for 24 hours. After incubation, 10 ul MTT reagent was added to each well and 
cells were incubated for another three hours. Next, 100 ul crystal resolving solution was added to 
each well. Absorbance at 595 nm was measured for each well after 18 hours of incubation at 
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37°C. Three biological replicates were conducted for each test and representative data were 
selected to present.  
Viruses, viral infection, and plaque assays 
The Western Reserve strain (ATCC VR-1354) of vaccinia virus was amplified in HeLa 
cells and purified according to a previously-published protocol (Cotter, Earl, Wyatt, & Moss, 
2015). Three recombinant vaccinia viruses, vEGluc, vIGluc, and vLGluc (kindly given by Dr. 
Bernard Moss), were used, which expressed the secreted gaussia luciferase reporter gene under 
well-defined early, intermediate, and late promoters, respectively. 
For the amplification and purification of vaccinia virus, a monolayer of HeLa cells was 
infected with vaccinia virus at a multiplicity of infection (MOI) of 0.01 for 48 hours. The 
infected cells were then collected, and the cell lysate was obtained through three freeze–thaw 
cycles. The cell lysate was then sonicated, and vaccinia virus stock was purified from it via 
sucrose gradient centrifugation.  
For viral infection, NHDFs or HeLa cells were placed in a 12-well plate at a density of 
0.4 x 106/well one day before infection. Next, cells were incubated with virus-containing 
medium (containing 2.5% FBS, 2 mM glutamine, and 1% penicillin-streptomycin) for the 
desired amount of time before samples were collected for titration. For HFKs, viruses were 
diluted in Gibco medium and incubated for the desired time. 
Viral titer was determined via plaque assay. For this assay, BS-C-1 cells were also 
prepared in the same way as described above, then infected with serially-diluted viral samples 
and incubated in EMEM medium (containing 2.5% FBS, 2 mM glutamine, 1% penicillin-
streptomycin, and 0.5% methyl cellulose) for 48 hours before staining with 0.1% crystal violet to 
count the number of plaques.  
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Gaussia luciferase assay 
NHDFs or HeLa cells were placed in a 12-well plate at a density of 0.4 x 105/well. The 
next day, cells were refreshed with medium containing DMSO or different chemical inhibitors, 
and then infected with vEGluc, vIGluc, or vLGluc at a MOI of 1. A 100-uL aliquot of medium 
was taken from each well after the desired incubation time and gaussia luciferase activity was 
measured with the Pierce Gaussia Luciferase Flash Assay Kit (Thermo Scientific). Next, 30 uL 
of media from each well were placed in a white plate and equal amounts of fresh luciferase 
substrates were added to each well. The reaction between luciferase and its substrates produced 
luminescence, which was measured with the GloMax Navigator System (Promega). Three 
biologal replicates were conducted for each experiment. The inhibition rate of gene expression 
was calculated by comparing gaussia luciferase light unit values for each sample to a control. 
Plaque assay 
Plaque assays were performed to measure the inhibition effects of chemical inhibitors on 
the replication of vaccinia virus. First, NHDFs or HeLa cells were placed in a 12-well plate at a 
density of 0.4 x 105/well. Attached cells were then infected with vaccinia virus (MOI of 1) and 
inoculated with DMSO or a serial concentration of chemical inhibitor. After a 24-hour 
incubation, cell lysates were obtained to measure viral titer via plaque assay. Three biological 
replicates were conducted and the average viral titer for each sample was calculated. 
Statistical analysis 
All experiments had three biological replicates and representative data were used for 
statistical analysis. T-tests were performed to assess differences between two groups, and 
significance was defined by a p-value ≤ 0.05. 
31 
Results 
Identification of JAK/STAT3 inhibitors that suppress replication of vaccinia virus 
To identify host components that are essential for the replication of vaccinia virus, we 
first generated an assay suitable for high-throughput screening based on a recombinant reporter 
vaccinia virus (vLGluc) that expresses secreted gaussia luciferase under the well-defined viral 
late promoter F17R. Over 3000 chemical compounds with known cellular targets from bioactive 
compound and FDA-approved drug libraries were tested for vaccinia virus inhibitors (Figure 2-1; 
Dr. Peng Chen, personal communication). Next, we tested the cytotoxicity of the primary hits on 
HeLa cells and observed their effects on the gaussia luciferase enzyme alone. In the meantime, 
we tested the antiviral effects of these inhibitors on the replication of vaccinia virus using 
vLGluc at MOIs of 0.01 and 2. The four parallel experiments confirmed that the change in 
gaussia luciferase luminescence in each well represented the effects of the different chemicals on 
the replication of vaccinia virus. We identified and confirmed numerous inhibitors of vaccinia 
virus, many of which target the JAK/STAT3 pathway. Based on our chemical screen results, we 
propose that the JAK/STAT3 pathway is essential for the replication of vaccinia virus. 
Chemical inhibitors of the JAK/STAT3 pathway repress gene expression in vaccinia virus 
To test the effect of inhibiting the JAK/STAT3 pathway on the replication of vaccinia 
virus, we chose small molecule inhibitor SC144 (IL-6 receptor inhibitor), AZ960 (JAK2 
inhibitor), and stattic and niclosamide (STAT3 inhibitors). The JAK/STAT3 pathway is closely 
related to cell proliferation and apoptosis, and the inhibitors of this pathway have inhibitory 
effects on cell viability at certain concentrations (Yu et al., 2009). All inhibitors used here are 
reported to inhibit cell viability for several types of cell lines  (Gozgit et al., 2008; Ren et al., 
2010; Schust et al., 2006; Xu et al., 2013). Because an elevated apoptosis rate in the host cell 
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suppresses the replication of vaccinia virus (Kvansakul et al., 2008), we first optimized the 
working concentrations of chemical inhibitors at which there was no significant toxic effect on 
cell viability. MTT assays were performed to test the effects of JAK/STAT3 inhibitors on cell 
viability. NHDFs were seeded in a 96-well plate and incubated with media containing chemical 
inhibitors for 8 hours. MTT assays were then performed according to the manufacturer’s 
protocol and absorbance from each well was measured using a microplate reader. SC144, 
AZ960, and Stattic exhibited no significant toxicity effects on NHDFs at their indicated 
concentrations (1 uM, 3 uM, and 3 uM, respectively), whereas niclosamide treatment 
significantly (>30%) improved NHDF cell viability at a concentration of 1 uM (Figure 2-3 D). 
The lifecycle of the vaccinia virus consists of cell entry, gene expression, DNA 
replication, virion assembly, and exit (Moss, 2013a). Vaccinia virus gene expression has three 
stages and is regulated in a cascading manner (Yang, Maruri-Avidal, Sisler, Stuart, & Moss, 
2013). Each stage of vaccinia virus gene expression produces different factors and enacts 
different functions to interact with host cell components (Van Vliet et al., 2009). To test which 
stages of vaccinia virus gene expression were affected by inhibiting the JAK/STAT3 pathway, 
we used three recombinant reporter vaccinia viruses (vEGluc, vIGluc, and vLGluc) expressing 
gaussia luciferase under well-defined early, intermediate, and late vaccinia virus promoters, 
respectively. NHDFs were infected with vEGluc, vIGluc, or vLGluc at MOIs of 1 in the presence 
of four chemical inhibitors. Culture media from each well were collected at 4, 8, and 12 hours 
after infection and measured for gaussia luciferase activity. Early, intermediate, and late gene 
expression was measured 4, 8 and 12 hours post infection, respectively. 
All four JAK/STAT3 inhibitors used here were able to significantly reduce all three 
stages of vaccinia virus gene expression at concentrations that did not decrease cell viability 
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(Figure 2-3 A – C). SC144, an IL-6 receptor (GP130) inhibitor, can repress intermediate and late 
gene expression by approximately 80-fold and 30-fold, respectively, and inhibit early gene 
expression up to 3-fold. AZ960, a selective JAK2 inhibitor, displayed a similar trend in 
regulating all three stages of gene expression, with an inhibition effect of approximately 8-fold. 
The two STAT3 inhibitors, Stattic and niclosamide, showed different effects on early gene 
expression, but similar inhibitory effects on intermediate and late gene expression 
(approximately 20-fold and 8-fold, respectively). Stattic repressed early gene expression by 
approximately 8-fold, whereas niclosamide repressed early gene expression by approximately 
15-fold. Even with different extensions, all four inhibitors showed significant inhibitory effects 
towards all three stages of vaccinia virus gene expression. Because vaccinia virus gene 
expression is regulated in a cascading manner, these results indicate that the JAK/STAT3 
pathway was required for vaccinia virus replication starting from the early gene expression stage. 
JAK/STAT3 inhibitors repress gene expression of vaccinia virus in keratinocytes 
In a previously-published paper, the inhibition of the JAK/STAT3 pathway resulted in 
increased replication of vaccinia virus in keratinocytes (He et al., 2014), which contradicts our 
findings. To clear this discrepancy, we tested the effects of two STAT3 inhibitors on vaccinia 
virus late gene expression, as well as their effects on replication in HFKs. As described 
previously, HFKs were seeded in a 24-well plate and infected with vLGluc at a MOI of 1 for 12 
hours. Culture media were collected and used for the gaussia luciferase assay. Both Stattic and 
niclosamide effectively reduced vaccinia virus late gene expression by approximately 5-fold 
(Figure 2-4), indicating a suppressing effect in a different cell type. 
34 
The cytotoxicity of niclosamide on NHDFs and the inhibitory effects of niclosamide on 
replication of vaccinia virus 
Niclosamide, a small chemical inhibitor that targets STAT3, is also an FDA-approved 
drug against parasitic infection. In previous experiments, we noticed that niclosamide showed 
potent inhibitory effects on vaccinia virus gene expression at 1 uM concentration. Niclosamide 
therefore has the potential to be repurposed as an antiviral drug for poxvirus infection. To further 
characterize this chemical, we measured the cytotoxicity of niclosamide on NHDFs with an MTT 
assay and its inhibitory effects on vaccinia virus replication with a plaque assay.  
 NHDFs were treated with a series of concentrations of niclosamide. An MTT assay was 
performed to measure cell viability in each well. In the 0 – 50 uM concentration range, 
niclosamide had no significant toxicity effects on NHDFs. To determine the inhibitory effects of 
niclosamide on vaccinia virus replication, NHDFs were plated in a 12-well plate and infected 
with wild-type vaccinia virus (Western Reserve strain) at a MOI of 1 in the presence of 
niclosamide. A series of concentrations of niclosamide were used to determine the inhibitory 
effects of niclosamide on vaccinia virus replication and a plaque assay was performed. 
Niclosamide started to repress vaccinia virus at a concentration of 1 uM and reached its 
maximum effect at a concentration of 1.5 uM, which caused approximately a 10-fold reduction 
in viral titer (Figure 2-5).  
The cytotoxicity of SC144 on NHDFs and the inhibitory effects of SC144 on replication of 
vaccinia virus in NHDFs 
In addition to niclosamide, another small molecule inhibitor, SC144, also had strong 
effects on vaccinia virus gene expression in our previous experiments. SC144 is a bioactive 
compound that specifically targets GP130, which is a subunit of the IL-6 receptor, and further 
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blocks activation of the JAK/STAT3 pathway (Xu et al., 2013). SC144 can repress vaccinia virus 
gene expression at a concentration of 1 uM. Our objective was to further characterize SC144 and 
measure the inhibitory effects of SC144 on vaccinia virus and the cytotoxicity effects of SC144 
on NHDFs. In NHDFs, SC144 started to decrease cell viability at a concentration of 5 uM and 
reached its maximum effect at a concentration of 30 uM. SC144 repressed replication of vaccinia 
virus at 1 uM and reached its maximum effect at a concentration of 2.5 uM (Figure 2-6). 
The cytotoxicity of SC144 on HeLa cells and the inhibitory effects of SC144 on vaccinia 
virus in HeLa cells 
To test if the inhibitory effect of SC144 on the replication of vaccinia virus is cell type-
dependent, we measured the cytotoxicity effects of SC144 on HeLa cells and the inhibitory 
effects on vaccinia virus replication in HeLa cells. MTT assays and plaque assays were 
performed with HeLa cells to measure the effect of SC144 on HeLa cell viability and vaccinia 
virus replication in HeLa cells. Compared to NHDFs, SC144 showed lower toxicity on HeLa 
cells, starting to show cytotoxicity to HeLa cells at a concentration of 25 uM. SC144 repressed 
vaccinia virus replication at a concentration of 2.5 uM (Figure 2-7). 
Discussion 
The objective of this study was to identify host cell components that were required for 
efficient replication of the vaccinia virus. Our chemical screening of vaccinia virus inhibitors 
revealed that the JAK/STAT3 pathway is required for vaccinia virus replication. This 
phenomenon was consistent when we tested the effects of four inhibitors of the JAK/STAT3 
pathway on vaccinia virus replication in NHDFs and HFKs. The JAK/STAT3 signaling pathway 
is involved in many physiological processes, including immune response and cell proliferation 
(Takeda et al., 1998); however, the role of the JAK/STAT3 pathway regarding viral infections is 
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complex (Kuchipudi, 2015). Our unbiased chemical screening data suggest that this pathway is 
required for efficient vaccinia virus replication. In addition, we tested which steps of vaccinia 
virus replication required the JAK/STAT3 signaling pathway using a reporter recombinant 
vaccinia virus. Our data suggest that inhibition of the JAK/STAT3 signaling pathway suppresses 
all three stages of gene expression for the vaccinia virus. Since the gene expression of vaccinia 
virus is regulated in a cascading manner (Yang et al., 2013), we believe that vaccinia virus 
requires the JAK/STAT3 pathway from the early gene expression stage, but may also require it 
during later gene expression. 
The role of the JAK/STAT3 signaling pathway in vaccinia virus replication has 
previously been shown by He et al. (2014), who observed that mice developed larger vaccinia 
lesions and higher viral titers when topically treated with Stattic, a STAT3 inhibitor. Cultured 
human and murine keratinocytes produced more infectious particles when treated with Stattic, as 
well. He et al. argued that the inhibition of STAT3 repressed the type I interferon response in 
keratinocytes, and therefore the JAK/STAT3 signaling pathway suppressed vaccinia virus 
replication. Our unbiased chemical screening results and data regarding multiple JAK/STAT3 
inhibitors are not consistent with their finding. We also tested two STAT3 inhibitors, Stattic and 
niclosamide, on vaccinia virus gene expression in human keratinocytes. We found that both 
Stattic and niclosamide treatment repressed vaccinia virus replication in human keratinocytes 
after 24 hours of incubation. The discrepancy in effects of JAK/STAT3 inhibitors on vaccinia 
virus replication could be explained by the fact that the replication of vaccinia virus requires 
STAT3 signaling at the cellular level, whereas inhibition of STAT3 activity damages adaptive 
immune response in animals, leading to more virulent symptoms. Although we cannot explain 
the discrepancy between our findings and the aforementioned study using a cell culture system, 
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we reproducibly observed the same results using multiple JAK/STAT3 inhibitors and multiple 
cell types. Thus, we have concluded that the JAK/STAT3 pathway is required for efficient 
replication of the vaccinia virus in culture cells. 
 Highly elevated STAT3 activation is a marker of poor clinical outcomes for several 
types of cancer patients. Vaccinia virus is an oncolytic agent that has been studied to treat cancer. 
STAT3 activation supporting vaccinia virus replication explains why vaccinia virus 
preferentially replicates in cancer cells (Zeh et al., 2015). The link between STAT3 and vaccinia 
virus is supported in this study, providing some insights concerning how vaccinia virus 
manipulates the JAK/STAT3 pathway. Vaccinia virus is reported to inhibit host immune 
response and apoptosis, and the JAK/STAT3 pathway is involved in both of these physiological 
processes. Activation of the JAK/STAT3 pathway is both advantageous and disadvantageous for 
the replication of vaccinia virus. We have demonstrated that vaccinia virus somehow utilizes the 
JAK/STAT3 pathway to promote virus replication. 
In addition, we observed that two inhibitors of the JAK/STAT3 pathway, niclosamide 
(STAT3 inhibitor) and SC144 (GP130 inhibitor), can repress vaccinia virus replication at a very 
low working concentration (1 uM). Further characterization showed that these two chemicals 
have great potential to treat poxvirus infections. Regarding niclosamide, this FDA-approved drug 
has already shown anti-viral effects on multiple types of viral infections (Jurgeit et al., 2012). In 
addition, niclosamide can effectively inhibit vaccinia virus replication in NHDFs and HFKs, 
which makes it a promising candidate for antiviral drug development. Similarly, SC144, a 
bioactive that targets GP130, repressed vaccinia virus replication in NHDF, HFKs, and HeLa 
cells. SC144 has inhibitory effects on several types of cancer cells (Xu et al., 2013), and our data 
suggest that SC144 has the potential to treat poxvirus infection as well. 
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In summary, we have demonstrated that the JAK/STAT3 pathway is required for efficient 
replication of the vaccinia virus and furthermore, two JAK/STAT3 inhibitors, niclosamide and 
SC144, have the potential to be antiviral drugs to treat poxvirus infection. 
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Figure 2-1 Schematic of chemical screen for inhibitors of vaccinia virus 
A: Trypsinized HeLa cells were infected with vLGluc at a MOI of 0.01 and placed in a 96-well 
plate. vLGluc-infected HeLa cells were then treated with different chemicals for 24 hours and 
gaussia luciferase activity was measured in the culture medium. 
B: Schematic of chemical screening process. For primary screen, vLGluc-infected HeLa cells (at 
MOI of 0.01) were placed in a 96-well plate in the presence of DMSO or different chemical 
compounds (at a concentration of 10 uM) from Selleck Chemicals and FDA-approved drug 
libraries. To confirm that the primary hits affect vaccinia virus replication, we performed a 
second screen and assessed the toxicity effects of the primary hits on the gaussia luciferase 
enzyme and HeLa cell viability. In addition, we used high (MOI of 2) and low (MOI of 0.01) 
amounts of vLGluc to infect HeLa cells and to test the effects of the primary hits on vaccinia 
virus replication. For cytotoxicity effects, HeLa cells were incubated with DMSO or chemical 
compounds for 24 or 48 hours and an MTT assay was performed to measure cell viability after 
treatment. Gaussia luciferase enzymes were incubated with DMSO or chemical compounds, and 
a gaussia luciferase assay was performed to measure gaussia luciferase activity after treatment. 
Secondary screening revealed numerous inhibitors of vaccinia virus replication, many of which 
targeted the JAK/STAT3 pathway. 
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Figure 2-2 Small chemical inhibitors target the JAK/STAT3 pathway 
SC144 inhibits GP130, a subunit of the IL-6 receptor, and further represses activation of the 
JAK/STAT3 pathway. AZ960, another small chemical inhibitor, competitively binds to ATP-
binding sites of JAK2 and blocks the JAK/STAT3 signaling pathway. In contrast, niclosamide 



















































































Figure 2-3 Effects of inhibitors of the JAK/STAT3 pathway on gene expression in vaccinia 
virus 
A – C: Effects of inhibitors of the JAK/STAT3 pathway on early, intermediate, and late gene 
expression by vaccinia virus. Normal human dermal fibroblasts (NHDFs) were plated in a 12-
well plate and infected with vEGluc (early), vIGluc (intermediate), or vLGluc (late) vaccinia 
virus at a MOI of 1 in the presence of DMSO, Stattic (3 uM), niclosamide (1 uM), AZ960 (3 
uM), or SC144 (1 uM). Culture media from each well were used to measure gaussia luciferase 
activity 4, 8, and 12 hours after infection. (A) Early gene expression (vEGluc) was measured 
based on gaussia luciferase activity. (B) Intermediate gene expression (vIGluc) was measured 8 
hours post infection. (C) Late gene expression (vLGluc) was measured 12 hours post infection. 
D: Toxicity effects of inhibitors of the JAK/STAT3 pathway on NHDFs. NHDFs were placed in 
a 96-well plate and incubated with DMSO, Stattic (3 uM), niclosamide (1 uM), AZ960 (3 uM), 
and SC144 (1 uM) for 8 hours. An MTT assay was performed to measure cell viability. Three 

































































































































































































Figure 2-4 Effects of STAT3 inhibitors on late gene expression of vaccinia virus in primary 
human keratinocytes (HFKs) 
HFKs were placed in a 24-well plate and infected with the recombinant vaccinia virus vLGluc at 
a MOI of 1 in the presence of DMSO, Stattic (5 uM), or niclosamide (1 uM). At 12 hours post 
infection, a gaussia luciferase assay was performed with culture media from each well to 



































Figure 2-5 The cytotoxicity and the inhibitory effects of niclosamide on normal human 
dermal fibroblasts (NHDFs) and replication of vaccinia virus 
A: NHDFs were placed in a 96-well plate and incubated with a series of concentrations of 
niclosamide for 24 hours. An MTT assay was then performed to measure cell viability of 
NHDFs. 
B: NHDFs were placed in a 12-well plate and infected with vaccinia virus (Western Strain) at a 
MOI of 1 in the presence of DMSO or the indicated concentration of niclosamide. A plaque 




























































Figure 2-6 The cytotoxicity and the inhibitory effects of SC144 on NHDFs and replication 
of vaccinia virus 
A: NHDFs were placed in a 96-well plate and incubated with a series of concentrations of SC144 
for 24 hours. Cell viability was measured by MTT assay. 
B: NHDFs were placed in a 12-well plate and infected with vaccinia virus at a MOI of 1 in the 
























































Figure 2-7 The cytotoxicity and the inhibitory effects of SC144 on HeLa cells and 
replication of vaccinia virus in HeLa cells 
A: HeLa cells were placed in a 96-well plate and incubated with the indicated concentration of 
SC144 for 24 hours. Cell viability was measured by MTT assay. 
B: HeLa cells were placed in a 12-well plate and infected with vaccinia virus at a MOI of 1 in 

























































Chapter 3 - Construction of recombinant vaccinia virus with an IPTG-inducible 
phosphatase, H1 
Abstract 
We observed that the phosphorylation of STAT3 was downregulated in the early stages 
of vaccinia virus infection. Vaccinia virus encodes a dual-specific viral phosphatase, H1, and we 
proposed that H1 is responsible for the dephosphorylation of STAT3. To test this hypothesis, we 
generated a recombinant vaccinia virus, viH1L, based on a hybrid vaccinia virus system (Vac/ 
T7). In the absence of the inducer isopropyl β-D-1-thiogalactopyranoside (IPTG), the expression 
of the viral phosphatase H1 was suppressed (viH1), whereas in the presence of IPTG, the 
expression of viral phosphatase could be restored (viH1+IPTG). We found that recombinant 
viH1L produced more infectious particles in the presence of IPTG in comparison to viH1L 




The phosphorylation and dephosphorylation of proteins play an important role in 
modulating physiological activities in eukaryotic cells. Viruses are known to manipulate host cell 
machinery by regulating host cellular phosphorylation events. Vaccinia virus encodes two 
kinases, B1 and F10, and one phosphatase, H1, which indicates that regulation of 
phosphorylation events is also important for vaccinia virus infection (Greseth, Carter, Terhune, 
& Traktman, 2017). The dual-specificity phosphatase H1, an essential factor for vaccinia virus 
infection, regulates the dephosphorylation of viral and host proteins. Repression of H1 results in 
vaccinia virus with low infectivity, whereas loss of H1 leads to non-viable virus (Liu, Lemon, & 
Traktman, 1995). H1 is released from the viral core during viral core activation, which is 
characterized by the disulfide-bonded viral core protein being reduced and releasing factors and 
enzymes encapsulated in the viral core. 
H1 can also dephosphorylate host the signal transducer and activator of transcription 
factor 1 (STAT1) protein to repress host interferon response (Najarro, Traktman, & Lewis, 
2001). Type I interferon response, which is the first immune defense system against viral 
evasion, is mediated by the Janus kinase (JAK)/STAT1 pathway. Activating the JAK/STAT1 
pathway induces the expression of interferon stimulated genes (ISGs), which further activates 
innate and adaptive immune responses, and leads the host to an antiviral state (Ivashkiv & 
Donlin, 2014). Upon phosphorylation, reciprocal interaction between a phosphorylated tyrosine 
(701Y) residue and the SH2 domain leads to the formation of a STAT1 dimer. Following 
dimerization, STAT1 translocates to the nucleus and binds to DNA to regulate gene expression. 
H1 is reported to dephosphorylate the STAT1 protein and block its nucleus translocation in a 
dose-dependent manner (Koksal, Nardozzi, & Cingolani, 2009). Structural analysis has revealed 
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that dimeric H1 is capable of recognizing STAT1 after its dimerization, dephosphorylating its 
tyrosine (701Y) residue, and blocking its nuclear translocation. 
Signal transducer and activator of transcription 3 (STAT3), which shares many common 
features with the STAT1 protein, is also involved in vaccinia virus infection. To determine the 
dynamic of phosphorylation level change of STAT3 during vaccinia virus infection, we used 
immunoblotting analysis and blotted vaccinia virus-infected cell lysate against tyrosine-
phosphorylated STAT3 antibodies. Immunoblotting results revealed that STAT3 
phosphorylation is downregulated in vaccinia virus-infected cells in the early stage of infection, 
although the level is recovered later. We therefore proposed that viral phosphatase H1 is 
responsible for the dephosphorylation of STAT3 in the early stage of vaccinia virus infection. To 
test this hypothesis, we generated a recombinant viH1L vaccinia virus in which the expression of 
H1 was experimentally controlled. We expected that repression of H1 in vaccinia virus would 
interfere with the dephosphorylation events of STAT3 in vaccinia virus-infected cells. 
Materials and methods 
Cell cultures 
All cells were cultured in a 37°C incubator with a supplement of 5% CO2. HeLa cells 
(ATCC CCL-2) and normal human dermal fibroblasts (NHDFs; ATCC PCS 201-010) were both 
cultivated in Dulbecco’s Modified Eagle Medium (DMEM) with the addition of 10% fetal 
bovine serum (FBS), 2 mM glutamine, and 1% penicillin-streptomycin. BS-C-1 cells were 
cultured in Eagle’s Minimum Essential Medium (EMEM) with the addition of 10% FBS, 2 mM 
glutamine, and 1% penicillin-streptomycin. 
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Viral infection and titration 
The Western Reserve (WR) strain (ATCC VR-1354) of vaccinia virus was amplified and 
purified, as described previously (Cotter et al., 2015). For viral infection, the desired amount of 
viral stock was diluted in culture medium (contain 2.5% FBS), and cells were incubated with 
infectious medium for an hour before the medium was refreshed. A plaque assay was performed 
with BS-C1 cells to determine the viral titer. 
Construction of an isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible recombinant 
vaccinia virus, viH1L 
Due to the insertion of edited green fluorescence protein (eGFP) into the viH1L 
construct, which was a foreign gene, we split the whole construct into three pieces. The upstream 
fragment contained 500 nucleotides of H1L gene, the middle fragment contained 20 nucleotides 
overlapped with the H1L gene and eGFP gene, and the downstream fragment contained 20 
nucleotides overlapped with the middle fragment and 500 nucleotides upstream of H1L (vH2R 
gene; Figure 3-4). PCR products of the three fragments were run on a DNA gel, and then the 
three PCR products were annealed and used as a template to amplify the whole construct via 
recombinant PCR technology. The viH1L construct possessed approximately 1800 nucleotides 
(Figure 3-4). HeLa cells were transfected with the viH1L construct for an hour and then infected 
with Vac/ T7 vaccinia virus (provided by Dr. Bernard Moss). Samples were collected for further 
purification and isolation. 
Preparation and isolation of the recombinant viH1L vaccinia virus 
BS-C-1 cells were infected with a serially-diluted sample of recombinant viH1L for 48 
hours. A single plaque that expressed green fluorescence was then picked and used to reinfect 
BS-C-1 cells. The steps described above were repeated for three rounds until all plaques in a 
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single well were green. The purified viH1L was then amplified in HeLa cells, as described 
previously (Cotter et al., 2015). 
Immunoblotting analysis 
NHDFs were seeded in a 12-well plate at a density of 0.4 x 106/well. Cells were infected 
with viH1L or WR vaccinia virus at a MOI of 1, either in the presence or absence of IPTG for 24 
hours. Cells were lysed with 80 ul RIPA buffer and agitated for 30 min.  Twenty ul of 5x western 
blot loading buffer was added and samples were incubated at 100°C for 5 minutes, followed by a 
cool down on ice before loading. Next, 30 ul of sample was loaded onto each 10-well 10% SDS-
PAGE gel and run for one and a half hours before transferring to a SDS-PAGE membrane for 
another hour. After the membrane was immunoblotted with anti-phos-STAT3 (Y705), anti-
STAT3, and GAPDH, the membrane was developed with chemiluminescent substrate (National 
Diagnostics, Atlanta, GA, United States). 
Results and discussion 
Phosphorylation of STAT3 decreases in vaccinia virus-infected cells, whereas total STAT3 
is enriched in the cell nucleus 
The JAK/STAT3 pathway can transduce extracellular signals to the cell nucleus via a 
series of intracellular phosphorylation events. The first step of STAT3 activation by JAKs is 
tyrosine phosphorylation at a single site near the C-terminal (Y705) of STAT3 in response to 
extracellular stimuli. Following tyrosine phosphorylation, a pair of STAT3 proteins dimerizes 
and translocates to the cell nucleus to regulate gene expression by binding to DNA regulatory 
elements. After establishing the fact that inhibitors of the JAK/STAT3 pathway repress vaccinia 
virus infection and replication, we were also interested in its activation level in NHDFs during 
vaccinia virus infection. After infecting NHDFs with WR vaccinia virus at a MOI of 1, we 
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determined the STAT3 tyrosine (Y705) phosphorylation level in NHDFs after vaccinia virus 
infection using immunoblotting analysis (Figure 3-1B). Another lab member, Dr. Shuai Cao, was 
conducting research on the localization of STAT3, however, and observed that the total STAT3 
was enriched in the cell nucleus during vaccinia virus infection. The confocal image showed that 
STAT3 translocated to the cell nucleus 4 hours after vaccinia virus infection (Figure 3-1B; Dr. 
Shuai Cao, personal communication). It has previously been reported that unphosphorylated 
STAT3 can also function as a signal transducer and be activated by extracellular signals (Yang et 
al., 2007), and our data indicated that unphosphorylated STAT3 might play an important role in 
vaccinia virus infection. The dephosphorylation of STAT3 in the early stage of vaccinia virus 
infection shared many similarities with the dephosphorylation of STAT1 in the early stage of 
vaccinia virus infection (Najarro et al., 2001), and it has been reported that viral H1 is 
responsible for the dephosphorylation of STAT1. The objective of this project was to generate a 
recombinant vaccinia virus, viH1L, in which the expression of H1 could be experimentally 
controlled. 
Construction of the IPTG-inducible recombinant viH1L vaccinia virus expressing green 
fluorescent protein (GFP) reporter gene 
It has been previously reported that vaccinia virus encodes the phosphatase H1 to 
dephosphorylate STAT1 during infection. Because STAT1 and STAT3 share similar structures 
and activation pathways, we propose that viral phosphatase H1 is also responsible for the 
reduction of STAT3 phosphorylation during vaccinia virus infection. To investigate whether 
repression of H1 expression results in a reduction of STAT3 phosphorylation, we first generated 
an IPTG-inducible viH1L recombinant vaccinia virus in which H1 expression was controlled by 
the presence of the inducer in culture medium. 
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The recombinant viH1L vaccinia virus is based on a hybrid vaccinia virus system (Vac/ 
T7) described previously (Alexander, Moss, & Fuerst, 1992). The Vac/ T7 vaccinia virus system 
consists of a constitutively expressed Escherichia coli lac repressor and a lac operon, which is 
inserted before the T7 polymerase gene. In the presence of the inducer (IPTG), lac repressors are 
inactive and lose their repression effect on the lac operon and T7 polymerase. The expression of 
T7 polymerase can thus induce T7 promoter-controlled gene expression (Figure 3-2). 
Homologous recombination frequently occurs in DNA viruses and plays an important role in 
viral evolution. When DNA fragments share similar sequences with the vaccinia virus genome 
during viral infection, these sequences can exchange with each other. Recombinant viH1L was 
generated based on homologous recombination (Figure 3-4A). After several rounds of 
purification and isolation, recombinant viH1L that expressed reporter eGFP was successfully 
generated (Figure 3-4B). Then we confirmed the recombinant viH1L with PCR technology and 
Sanger sequencing (Figure 3-5&6). 
Repression of H1 phosphatase in vaccinia virus decreases the production of infectious 
particles 
To characterize this viH1L recombinant virus, we first amplified viH1L viruses either in 
the presence or absence of the inducer IPTG in culture media, and then determined viral titer 
using a plaque assay. In the presence of IPTG, viH1L produced 7.5-fold more infectious particles 
than in the absence of IPTG (Figure 3-7). In conclusion, inhibition of H1 gene expression in 
vaccinia virus reduced the production of infectious particles (Figure 3-7). This is consistent with 
a previous study (Liu et al., 1995), which reported that viral H1 phosphatase was essential for 
vaccinia virus replication, as deletion of H1 resulted in non-viable virus. Our data confirmed that 
repression of H1 in vaccinia virus leads to decreased production of infectious particles. In 
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conclusion, we successfully generated a recombinant viH1L vaccinia virus in which the 
expression of H1 could be controlled. 
Future perspectives 
Viral phosphatase has inhibitory effect on the STAT1 phosphorylation, and we proposed 
that this viral protein could dephosphorylate STAT3 during vaccinia virus infection as well. With 
successful generation of the IPTG inducible viH1L recombinant vaccinia virus, we can test the 
effects of H1 repression on the phosphorylation of STAT3 during infection. Next step for this 
project would involve confirm that the expression of H1 can be induced by additional IPTG 
using Western blotting analysis. Since the STAT1 was dephosphorylated by H1, the repression 
of vH1 should increase the phosphorylation level of STAT1 in vaccinia virus-infected cells 
(Koksal, Nardozzi, & Cingolani, 2009). We proposed to test the phosphorylation level of STAT3 
in the presence of absence of IPTG by Western blotting analysis in viH1L-infected NHDFs and 
used the phosphorylated STAT1 level change as a control. If the H1 phosphatase was responsible 
for the dephosphorylation of STAT3, repression of H1 would reduce the dephosphorylation of 
STAT3 in vaccinia virus-infected NHDFs. 
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Figure 3-1 Phosphorylation of STAT3 in vaccinia virus-infected cells and total STAT3 in 
the cell nucleus 
A: Immunoblotting image of the phosphorylated tyrosine (Y705) showing changes in STAT3 
levels during vaccinia virus infection. Normal human dermal fibroblasts (NHDFs) were infected 
with vaccinia virus at a MOI of 1 and cell lysate was collected at the indicated time points after 
infection for immunoblotting analysis. 
B: Confocal image of mock and vaccinia virus-infected NHDFs. Mock and vaccinia virus-
infected NHDFs were stained with total STAT3 antibodies 4 hours post infection and the cell 
nucleus was stained with DAPI. (This experiment in panel B was conducted by Dr. Shuai Cao 


















Figure 3-2 IPTG-inducible Vac/T7 recombinant vaccinia virus system 
In the absence of IPTG, the Vac/T7 recombinant vaccinia virus constitutively expresses lac 
repressor (lacI) that bind to lac operon (lacO) and inhibit the expression of T7 polymerase. In the 
presence of IPTG, lac repressors were released from the lac operon which lead to the expression 


































Figure 3-3 Generation of the recombinant vaccinia virus viH1L 
A: Schematic showing generation of the viH1L construct via PCR technology. Fragments 1 and 
3 were generated through PCR using vaccinia virus as a template, whereas fragment 2 used 
edited green fluorescent protein (eGFP) as a template. Overlapping PCR was then used to 
generate the full viH1L insertion construct. 


























Figure 3-4 Generation of the recombinant vaccinia virus viH1L through PCR and 
recombinant technology 
A: Schematic showing the generation of the recombinant vaccinia virus viH1L through PCR and 
recombinant technology. 
B: HeLa cell were transfected with viH1L insertion constructs and infected with Vac/T7 
recombinant vaccinia virus for 24 hours. Plaque assay was performed to isolate the recombinant 
viH1L. Under microscope, recombinant viH1L infected BS-C1 cells exhibit bright green 
























Figure 3-5 Confirmation of successful generation of the three fragments of recombinant 
vaccinia virus viH1L by PCR 
HeLa cells were infected with recombinant viH1L for 24 hours and cell lysates were used to 
extract the recombinant viH1L DNA. We used the DNA extracts as template and primer pairs as 
shown above to amplify fragment A, B, and C, respectively. Next, the amplified fragments were 
run in a DNA gel. 
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Figure 3-6 Confirmation of successful generation of the recombinant vaccinia virus viH1L 
by Sanger sequencing 
Fragment C from Figure 3-5 was used as template for sanger sequencing and sequenced from the 
right end (H1L gene end). The sanger sequencing result was analyzed with Genesis software. 















Figure 3-7 Effects of the presence of IPTG on the production of infectious particles by the 
recombinant vaccinia virus viH1L and the Western Reserve (WR) strain of vaccinia virus 
HeLa cells were infected either with WR vaccinia virus or recombinant viH1L in the presence or 
absence of 100 uM IPTG for 24 hours. Virus samples were collected and diluted with cell culture 
medium. Ten-fold dilutions of virus samples were used to infect BS-C1 cells and plaque assay 











Chapter 4 - Summary and future perspectives 
The objective of this study was to identify the host cell components that were required for 
vaccinia virus to successful infect a cell. We identified and verified that the JAK/STAT3 
pathway is essential for efficient replication of the vaccinia virus. Moreover, we discovered that 
STAT3 was enriched in the cell nucleus while phosphorylated (Y705) STAT3 was 
downregulated in vaccinia virus-infected cells. 
The JAK/STAT3 pathway regulates both the host immune response and cell proliferation 
(Johnson et al., 2018). Vaccinia virus has been reported to repress both the host immune 
response and the cell apoptosis pathways during infection (Seet et al., 2003). Activation of the 
JAK/STAT3 signaling pathway is both advantageous and disadvantageous for viral replication 
(Suarez et al., 2018). Our data suggest that the vaccinia virus requires the JAK/STAT3 pathway 
during infection. Contrary to common knowledge regarding the JAK/STAT3 signaling pathway, 
our confocal image showed that STAT3 was enriched in vaccinia virus-infected NHDFs, 
whereas our immunoblotting image revealed that phosphorylated (Y705) STAT3 was 
downregulated during infection. The activation of STAT3 commonly involves it being 
phosphorylated on its tyrosine (Y705) residue, followed by its dimerization and translocation to 
the cell nucleus to enact its functions. The enrichment of STAT3 in the cell nucleus in vaccinia 
virus-infected cells while its total phosphorylation level was downregulated suggests that 
unphosphorylated STAT3 plays an important part in vaccinia virus replication. Indeed, 
unphosphorylated STAT3 has been reported to regulate gene expression (Yang et al., 2007), 
although the physiological role of unphosphorylated STAT3 is not fully explored. Our data 
suggest that unphosphorylated STAT3 is involved in vaccinia virus infection. Questions remain, 
however. How does vaccinia virus manipulate the level of phosphorylated STAT3 protein during 
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infection? What is the role of the JAK/STAT3 signaling pathway in vaccinia virus replication? 
The unphosphorylated form of the STAT3 protein has been reported to interact with the NF-B 
pathway (Yang et al., 2007), which is known to be repressed during vaccinia virus replication. 
Unphosphorylated STAT3 may therefore regulate the replication of vaccinia virus by interacting 
with the NF-B pathway. Another hypothesis is that unphosphorylated STAT3 may directly 
regulate the host cell’s gene expression in a way that benefits vaccinia virus replication. We plan 
to test this particular theory in the future. 
In addition, we have shown that niclosamide and SC144 have the potential to be used as 
antiviral drugs to treat poxvirus infection. Niclosamide is an FDA-approved drug that is reported 
to inhibit multiple types of viral infections (Jurgeit et al., 2012). Here, we have reported that 
niclosamide can repress titers of vaccinia virus up to 10-fold at a concentration of 1.5 uM. The SI 
of niclosamide in NHDFs is over 100, which indicates that the chemical is a suitable candidate 
for drug development to treat poxvirus infection. SC144 is a novel small molecule inhibitor of 
the IL-6 receptor that is reported to inhibit certain types of cancer (Xu et al., 2013), but little is 
known regarding its effect on viral infection. Here, we have reported a novel function for this 
bioactive chemical and have shown that its effect on viral replication is cell type-independent. In 
the future, we intend to test these two chemicals on vaccinia virus replication in murine models. 
Both niclosamide and SC144 have the potential to be developed as anti-viral medicines, and 
further experiments could include investigating their effects on different cell types, testing them 
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